Safety and Pharmacokinetics in Human Volunteers of Taniborbactam (VNRX-5133), a Novel Intravenous β-Lactamase Inhibitor

James A Dowell, Daniel Dickerson, Tim Henkel, James A Dowell, Daniel Dickerson, Tim Henkel

Abstract

Taniborbactam (formerly VNRX-5133), an investigational β-lactamase inhibitor active against both serine- and metallo-β-lactamases, is being developed in combination with cefepime to treat serious infections caused by multidrug-resistant Gram-negative bacteria. This first-in-human study evaluated the safety and pharmacokinetics of single and multiple doses of taniborbactam in healthy adult subjects. Single doses of 62.5 to 1,500 mg taniborbactam and multiple doses of 250 to 750 mg taniborbactam every 8 h (q8h) for 10 days were examined; all taniborbactam doses were administered as a 2-h intravenous infusion. No subjects experienced serious adverse events or discontinued treatment due to adverse events. The most common adverse event in both placebo- and taniborbactam-treated subjects was headache. The pharmacokinetics of taniborbactam were similar to the pharmacokinetics reported for cefepime. Taniborbactam demonstrated dose-proportional pharmacokinetics with low intersubject variability. Following single doses and with extended sampling, the mean terminal elimination half-life ranged from 3.4 to 5.8 h; however, the majority of exposure was characterized by an earlier phase with a half-life of about 2 h. Following multiple dosing, there was minimal accumulation of taniborbactam in plasma. At steady-state, approximately 90% of the administered dose of taniborbactam was recovered in urine as intact drug. There was no appreciable metabolism observed in either plasma or urine samples. (This study is registered at clinicaltrials.gov under registration number NCT02955459.).

Keywords: VNRX-5133; beta-lactamase inhibitor; drug safety; first-in-human; pharmacokinetics; taniborbactam.

Figures

FIG 1
FIG 1
Mean taniborbactam plasma concentrations versus time following a single dose (single-ascending-dose part). Logarithmic concentration scale.
FIG 2
FIG 2
Mean taniborbactam plasma concentration versus time through the dosing interval (multiple-ascending-dose part). q8h, every 8 h. Logarithmic concentration scale.

References

    1. World Health Organization. Antibiotic resistance fact sheet. 2020. . Accessed 8 December 2020.
    1. Global Antibiotic Research and Development Partnership. 2020. Uniting against antibiotic resistance. .
    1. Logan LK, Weinstein RA. 2017. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis 215:s28–s36. 10.1093/infdis/jiw282.
    1. Zhanel GG, Lawson CD, Adam H, Schweizer F, Zelenitsky S, Lagacé-Wiens PRS, Denisuik A, Rubinstein E, Gin AS, Hoban DJ, Lynch JP, Karlowsky JA. 2013. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs 73:159–177. 10.1007/s40265-013-0013-7.
    1. Hecker SJ, Reddy KR, Totrov M, Hirst GC, Lomovskaya O, Griffith DC, King P, Tsivkovski R, Sun D, Sabet M, Tarazi Z, Clifton MC, Atkins K, Raymond A, Potts KT, Abendroth J, Boyer SH, Loutit JS, Morgan EE, Durso S, Dudley MN. 2015. Discovery of a cyclic boronic acid β-lactamase inhibitor (RPX7009) with utility vs class A serine carbapenemases. J Med Chem 58:3682–3692. 10.1021/acs.jmedchem.5b00127.
    1. Lomovskaya O, Sun D, Rubio-Aparicio D, Nelson K, Tsivkovski R, Griffith DC, Dudley MN. 2017. Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae. Antimicrob Agents Chemother 61:1–15. 10.1128/AAC.01443-17.
    1. Livermore DM, Warner M, Mushtaq S. 2013. Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother 68:2286–2290. 10.1093/jac/dkt178.
    1. Petty LA, Henig O, Patel TS, Pogue JM, Kaye KS. 2018. Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae. Infect Drug Resist 11:1461–1472. 10.2147/IDR.S150447.
    1. Daigle DM, Burns CJ. 2018. Kinetic mechanism & parameters of inhibition of KPC-2, CTX-M15, p99 AmpC and VIM-2 by the β-lactamase inhibitor VNRX-5133. Abstr O0606. Abstr 28th Eur Cong Clin Microbiol Infect Dis, Madrid, Spain.
    1. Liu B, Trout REL, Chu G-H, McGarry D, Jackson RW, Hamrick JC, Daigle DM, Cusick SM, Pozzi C, De Luca F, Benvenuti M, Mangani S, Docquier J-D, Weiss WJ, Pevear DC, Xerri L, Burns CJ. 2020. Discovery of taniborbactam (VNRX-5133): a broad-spectrum serine- and metallo-β-lactamase inhibitor for carbapenem-resistant bacterial infections. J Med Chem 63:2789–2801. 10.1021/acs.jmedchem.9b01518.
    1. Hamrick J, Chatwin C, John K, Pevear D, Burns C, Xerri L. 2018. The ability of broad-spectrum beta-lactamase inhibitor VNRX-5133 to restore bactericidal activity of cefepime in Enterobacteriaceae- and P aeruginosa-expressing Ambler class A, B, C and D enzymes is demonstrated using time-kill kinetics. Abstr P1545. Abstr 28th Eur Cong Clin Microbiol Infect Dis, Madrid, Spain.
    1. Hamrick JC, Docquier J-D, Uehara T, Myers CL, Six DA, Chatwin CL, John KJ, Vernacchio SF, Cusick SM, Trout REL, Pozzi C, De Luca F, Benvenuti M, Mangani S, Liu B, Jackson RW, Moeck G, Xerri L, Burns CJ, Pevear DC, Daigle DM. 2020. VNRX-5133 (taniborbactam), a broad-spectrum inhibitor of serine- and metallo-β-lactamases, restores activity of cefepime in Enterobacterales and Pseudomonas aeruginosa. Antimicrob Agents Chemother 64:e01963-19. 10.1128/AAC.01963-19.
    1. Vidales A, Hackel M, Wise M, Sahm D. 2020. Antimicrobial activity of cefepime in combination with taniborbactam (formerly VNRX-5133) against clinical isolates of Enterobacterales collected from global 2018–2019 surveillance. Abstr ASM Microbe Online. .
    1. Kalamatas J, Hackel M, Wise M, Sahm D. 2020. Antimicrobial activity of cefepime in combination with taniborbactam (formerly VNRX-5133) against a 2018–2019 surveillance collection of Pseudomonas aeruginosa. ASM Microbe Online. .
    1. Georgiou P-C, Siopi M, Tsala M, Lagarde C, Kloezen W, Donnelly R, Meletiadis J, Mouton J. 2018. VNRX-5133, a novel broad-spectrum beta-lactamase inhibitor, enhances the activity of cefepime against Enterobacteriaceae and P aeruginosa isolates in a neutropenic mouse thigh infection model. Abstr P1540.
    1. Weiss W, Pulse M, Nguyen P, Valtierra D, Peterson K, Carter K, Pevear D, Burns C, Xerri L. 2018. Efficacy of cefepime/VNRX-5133, a novel beta-lactamase inhibitor combination, against cephalosporin-resistant, ESBL-producing K. pneumoniae in a murine lung-infection model. Abstr #O0600. Abstr 28th Eur Cong Clin Microbiol Infect Dis, Madrid, Spain.
    1. Abdelraouf K, Abuhussain SA, Nicolau DP. 2020. In vivo pharmacodynamics of new-generation β-lactamase inhibitor taniborbactam (formerly VNRX-5133) in combination with cefepime against serine-β-lactamase-producing Gram-negative bacteria. J Antimicrob Chemother 75:3601–3310. 10.1093/jac/dkaa373.
    1. Steiger SN, Comito RR, Nicolau DP. 2017. Clinical and economic implications of urinary tract infections. Expert Rev Pharmacoecon Outcomes Res 17:377–383. 10.1080/14737167.2017.1358618.
    1. Yahav D, Giske CG, Grāmatniece A, Abodakpi H, Tam VH, Leibovici L. 2020. New β-lactam-β-lactamase inhibitor combinations. Clin Microbiol Rev 34:e00115-20. 10.1128/CMR.00115-20.
    1. Geibel B, Dowell JA, Dickerson D, Henkel T. 2019. Pharmacokinetics of VNRX-5133 alone and combined with cefepime when co-administered with metronidazole. Abstr P1951. Abstr 29th Eur Cong Clin Microbiol Infect Dis, Amsterdam, Netherlands.
    1. Hospira, Inc. 2012. Maxipime (cefepime hydrochloride) [package insert]. .
    1. Drago L, De Vecchi E. 2008. The safety of cefepime in the treatment of infection. Expert Opin Drug Saf 7:377–387. 10.1517/14740338.7.4.377.
    1. Okamoto MP, Nakahiro RK, Chin A, Bedikian A. 1993. Cefepime clinical pharmacokinetics. Clin Pharmacokinet 25:88–102. 10.2165/00003088-199325020-00002.
    1. Frimodt-Møller N. 2002. Correlation between pharmacokinetic/pharmacodynamic parameters and efficacy for antibiotics in the treatment of urinary tract infection. Int J Antimicrob Agents 19:546–553. 10.1016/S0924-8579(02)00105-X.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner